Results 51 to 60 of about 48,590 (264)

Integration of Complete Plasmids Containing Bont Genes into Chromosomes of Clostridium parabotulinum, Clostridium sporogenes, and Clostridium argentinense

Toxins, 2021
At least 40 toxin subtypes of botulinum neurotoxins (BoNTs), a heterogenous group of bacterial proteins, are produced by seven different clostridial species.
Theresa J. Smith, Renmao Tian, Behzad Imanian, Charles H. D. Williamson, Shannon L. Johnson, Hajnalka E. Daligault, Kristin M. Schill   +6 more
doaj   +1 more source

Conjugative Botulinum Neurotoxin-Encoding Plasmids in Clostridium botulinum

PLoS ONE, 2010
Clostridium botulinum produces seven distinct serotypes of botulinum neurotoxins (BoNTs). The genes encoding different subtype neurotoxins of serotypes A, B, F and several dual neurotoxin-producing strains have been shown to reside on plasmids, suggesting that intra- and interspecies transfer of BoNT-encoding plasmids may occur.
Kristin M Marshall, Marite Bradshaw, Eric A Johnson   +2 more
openaire   +4 more sources

Management of Absent Upper Esophageal Sphincter Opening After Neurological Injury

The Laryngoscope, EarlyView.
This study evaluated the effects of swallowing therapy and cricopharyngeus (CP) muscle surgery on upper esophageal sphincter (UES) opening, oral intake, and airway protection in patients with absent UES opening following neurological injury. CP‐targeted surgeries were associated with improved bolus passage and oral intake, but persistent aspiration ...
Radhika Rawat, Cyrus W. Abrahamson, Kelly Rogers, Jonelyn Langenstein, Jaymie Bromfield, Arjun Seth, James A. Burns, Andrew P. Stein   +7 more
wiley   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Update on Non-Interchangeability of Botulinum Neurotoxin Products

Toxins
The growing use of botulinum neurotoxins (BoNTs) for medical and aesthetic purposes has led to the development and marketing of an increasing number of BoNT products.
Mitchell F. Brin, Mariana Nelson, Nazanin Ashourian, Amy Brideau-Andersen, John Maltman   +4 more
doaj   +1 more source

MDSGene Systematic Review of Common Forms of Dominant Hereditary Spastic Paraplegia: Novel Insights

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hereditary spastic paraplegia (HSP) is a neurodegenerative disorder characterized by progressive spasticity and lower limb weakness. The most common forms of autosomal dominant HSP are caused by pathogenic variants in SPAST (SPG4 or HSP‐SPAST), ATL1 (SPG3A or HSP‐ATL1), and REEP1 (SPG31 or HSP‐REEP1).
Ce Kang, Rajasumi Rajalingam, Zachary Walls, Jana Huang, Christine Sun, Laura I. Rudaks, Dennis Yeow, Ashar Rasheed, Jenny W. Zhang, Moath Hamed, Marianthi Breza, Susen Schaake, Chetan Vekhande, Jason Massa, Robyn E. Massa, Aakash Shetty, Carolyn M. Sue, Franca Cambi, Oksana Suchowersky, Franca Vulinovic, Sonja Petkovic, Christine Klein, Katja Lohmann, Connie Marras, Kishore R. Kumar   +24 more
wiley   +1 more source

The Pain in Dystonia Scale (PIDS)—Validation in Craniofacial and Upper Limb Dystonia

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Pain is one of the most disabling non‐motor symptoms in adult‐onset isolated dystonia (AOID). The Pain in Dystonia Scale (PIDS) was developed and validated in cervical dystonia. Its applicability to other focal subtypes remains unknown.
Veronica Bruno, Vittorio Velucci, Beatrice Achen, Marcello Mario Mascia, Antonella Muroni, Daniele Belvisi, Francesco Marchet, Laura Avanzino, Francesca Di Biasio, Roberto Erro, Cristiano Sorrentino, Lucio Marinelli, Flavio Villani, Antonio Pisani, Francesca Valentino, Angelo Fabio Gigante, Anna Castagna, Francesco Bono, Giovanni Cossu, Carlo Alberto Artusi, Carmen Terranova, Martina Petracca, Nicola Tambasco, Giovanni Defazio, Davide Martino   +24 more
wiley   +1 more source

The Hidden Burden of Hemifacial Spasm: A Systematic Review of Non‐Motor Symptoms

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hemifacial spasm (HFS) is a chronic neurological disorder characterized by involuntary contractions of facial muscles. Traditionally regarded as a motor condition, HFS encompasses a spectrum of non‐motor symptoms that are often overlooked but significantly affect patients’ quality of life.
Miriam Carvalho Soares, Jacy Bezerra Parmera, Pedro Augusto Sampaio Rocha‐Filho   +2 more
wiley   +1 more source

Botulinum Toxin for the Treatment of Tremors

Toxins
Tremor, an oscillatory movement disorder, is commonly encountered in clinical practice in the setting of a variety of etiologies, such as essential tremor and Parkinson’s disease. Despite its high prevalence, treatment options are somewhat limited.
Steven Bellows, Joseph Jankovic
doaj   +1 more source

Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins

Toxins, 2016
Botulinum neurotoxins are bacterial proteins that cause botulism, a life-threatening disease. Therapy relies mostly on post-intoxication antibody treatment. The only accepted method to measure the potency of, and to approve, antitoxin preparations is the
Osnat Rosen, Eyal Ozeri, Ada Barnea, Alon Ben David, Ran Zichel   +4 more
doaj   +1 more source